Roche Says Outlook Is Improving as Revenue Grows
16 October 2019 - 4:48PM
Dow Jones News
By Carlo Martuscelli
Roche Holding AG (ROG.EB) raised its guidance on Wednesday after
reporting that sales rose 9.5% in the period from January to
September.
Sales in the nine months totaled 46.07 billion Swiss francs
($46.16 billion), up from CHF42.08 billion a year earlier. U.S.
sales were particularly strong, rising 17% to CHF20.04 billion.
The Swiss drugmaker said it now expects high-single-digit sales
growth at constant exchange rates in 2019, with core earnings per
share increasing in line with sales.
Previously, the company had guided for mid-to-high-single-digit
growth at constant exchange rates.
Roche said a strong performance from multiple sclerosis drug
Ocrevus, as well as hemophilia medicine Hemlibra and cancer
medicines Tecentriq, Perjeta and Avastin helped to offset declining
sales of Herceptin and MabThera/Rituxan, which were hit by
competition from closely-resembling drugs.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 16, 2019 01:33 ET (05:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024